Article
Biochemistry & Molecular Biology
Vittoria Rimola, Tabea Osthues, Vanessa Koenigs, Gerd Geisslinger, Marco Sisignano
Summary: Oxaliplatin treatment leads to transient changes in TRPM8 channel activity, causing acute peripheral pain and neuropathic pain, which may be associated with activation of the PLC pathway and depletion of PIP2.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2021)
Article
Medicine, Research & Experimental
Wenli Yu, Zhenli Zheng, Wei Wei, Lei Li, Yidan Zhang, Yanyan Sun, Jing Cao, Weidong Zang, Jinping Shao
Summary: The study revealed that Raf1 interacts with OIP5 to participate in oxaliplatin-induced neuropathic pain, with OIP5 potentially being an ideal drug target for the treatment of such pain.
Article
Pharmacology & Pharmacy
Hichem Bouchenaki, Aurore Danigo, Amandine Bernard, Flavien Bessaguet, Laurence Richard, Franck Sturtz, David Balayssac, Laurent Magy, Claire Demiot
Summary: The study evaluated the effect of the ACE inhibitor ramipril in a mouse model of oxaliplatin-induced acute pain syndrome, showing that ramipril can prevent cold sensitivity and improve tactile sensitivity in treated mice.
FRONTIERS IN PHARMACOLOGY
(2021)
Review
Biochemistry & Molecular Biology
Ji Hwan Lee, Woojin Kim
Summary: Oxaliplatin, a commonly used chemotherapeutic agent, can induce peripheral neuropathy, but its mechanism is not yet clearly understood; the serotonergic system may play a role in neuropathic pain, but further research is needed to determine its exact role.
Article
Anesthesiology
Vincenzo Davide Aloi, Silvia Joao Poseiro Coutinho Pinto, Rita Van Bree, Katrien Luyten, Thomas Voets, Joris Vriens
Summary: Chemotherapy-induced peripheral neuropathic pain (CIPNP) is a common adverse effect in cancer patients receiving cytostatic drugs. Current treatment options for CIPNP are limited and unsatisfactory. This study suggests that TRPM3 could be a potential target for the treatment of neuropathic pain in chemotherapy patients.
Article
Neurosciences
Vanessa Pereira, Sylvain Lamoine, Melissa Cumenal, Stephane Lolignier, Youssef Aissouni, Anne Pizzoccaro, Laetitia Prival, David Balayssac, Alain Eschalier, Emmanuel Bourinet, Jerome Busserolles
Summary: Peripheral neuropathy induced by oxaliplatin is characterized by acute pain symptoms, primarily caused by ion channel expression modulations in dorsal root ganglia neurons. The downregulation of K+ channels, including TREK and TRAAK, is identified as an important factor contributing to oxaliplatin-induced hypersensitivity. NRSF and HDACs play crucial roles in the dysregulation of K+ channels.
MOLECULAR NEUROBIOLOGY
(2021)
Article
Clinical Neurology
Aida Marcotti, Jorge Fernandez-Trillo, Alejandro Gonzalez, Marta Vizcaino-Escoto, Pablo Ros-Arlanzon, Luz Romero, Jose Miguel Vela, Ana Gomis, Felix Viana, Elvira de la Pena
Summary: The study reveals that sigma-1 receptor antagonists can regulate TRPA1 channels in nociceptors, reducing pain in a mouse model of oxaliplatin neuropathy. This finding suggests a novel strategy for the treatment of chemotherapy-induced peripheral neuropathy and offers insights for the development of new therapeutics for neuropathic pain.
Article
Biochemistry & Molecular Biology
Jonathan Paulo Agnes, Barbara dos Santos, Raquel Nascimento das Neves, Vitoria Maria Marques Luciano, Larissa Benvenutti, Fernanda Capitanio Goldoni, Roberta Giusti Schran, Jose Roberto Santin, Nara Lins Meira Quintao, Alfeu Zanotto-Filho
Summary: This study reveals the anti-allodynic effect of beta-caryophyllene (BCP) on oxaliplatin-induced peripheral neuropathy (OIPN) through CB2 receptor-dependent mechanisms and anti-inflammatory and antioxidant responses in the spinal cord.
Article
Biochemistry & Molecular Biology
Keun-Tae Park, Heejoon Jo, Bonglee Kim, Woojin Kim
Summary: Red ginger extract can prevent pain development induced by oxaliplatin and may do so by regulating the noradrenergic system.
Article
Biochemistry & Molecular Biology
Shuli Man, Lu Xie, Xuanshuo Liu, Genbei Wang, Changxiao Liu, Wenyuan Gao
Summary: Diosgenin extracted from fenugreek, yam, and other foods exhibits pharmacological activities that are effective in treating pain and nervous system diseases. This study investigated the mechanisms of diosgenin in chemotherapy-induced peripheral neuropathy (CIPN). The results showed that diosgenin protected PC12 cells from injury and reduced pain symptoms in CIPN mice. It inhibited oxidative stress, glial fibrillary acidic protein, and pro-inflammatory cytokines in the brain. Furthermore, it improved CIPN through modulation of the gut microbiota. In conclusion, diosgenin has the potential to ameliorate peripheral neuropathy and should be further studied for neuropathic pain treatment.
Article
Chemistry, Medicinal
Damiano Tanini, Simone Carradori, Antonella Capperucci, Lucrezia Lupori, Susi Zara, Marta Ferraroni, Carla Ghelardini, Lorenzo Di Cesare Mannelli, Laura Micheli, Elena Lucarini, Fabrizio Carta, Andrea Angeli, Claudiu T. Supuran
Summary: The new organochalcogenides with sulfonamide moiety act as potent inhibitors of CA isoforms, particularly hCA II and VII, showing potent neuropathic pain attenuating effects. They also enhance the anticancer drugs' capability in counteracting breast cancer MCF7 cell viability. The simultaneous anti-neuropathic pain and antiproliferative effects of the new chalcogenide-based CA inhibitors represent an innovative approach for managing side effects associated with clinically platinum drugs as antitumor agents.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
(2021)
Article
Biochemistry & Molecular Biology
Ji Hwan Lee, Jong Hee Choi, Jaihwan Kim, Tai Wan Kim, Ji-Young Kim, Geehoon Chung, Ik-Hyun Cho, Dae Sik Jang, Sun Kwang Kim
Summary: This study investigated the causal relationship between spinal microglial activation and oxaliplatin-induced peripheral neuropathy (OIPN) and explored the analgesic effects of syringaresinol on OIPN symptoms. Results showed that oxaliplatin treatment activated microglia, leading to inflammatory responses and pain induction. Syringaresinol treatment significantly ameliorated pain and suppressed microglial inflammatory responses.
Article
Biochemistry & Molecular Biology
Ji Hwan Lee, Daeun Min, Donghun Lee, Woojin Kim
Summary: Water extracts of Z. officinale significantly attenuated cold and mechanical allodynia induced by oxaliplatin, possibly by affecting the spinal 5-HT1A receptor.
Article
Neurosciences
Stacey Anne Gould, Matthew White, Anna L. Wilbrey, Erzsebet Por, Michael Philip Coleman, Robert Adalbert
Summary: Chemotherapy-induced peripheral neuropathy (CIPN) is a common side effect of cancer treatment associated with sensory axon degeneration. While WLDS and SARM1 have been shown to protect against axon degeneration, SARM1 deletion can alleviate acute oxaliplatin-induced pain, suggesting an independent mechanism of pain hypersensitivity in early stages. Targeting SARM1 may be a potential therapeutic approach for preventing oxaliplatin-induced acute neuropathic pain.
EXPERIMENTAL NEUROLOGY
(2021)
Article
Medicine, Research & Experimental
Gisele Graca Leite dos Santos, Anna Lethicia Lima Oliveira, Dourivaldo Silva Santos, Renan Fernandes do Espirito Santo, Daniela Nascimento Silva, Paulo Jose Lima Juiz, Milena Botelho Pereira Soares, Cristiane Flora Villarreal
Summary: The study found that MSC can completely reverse the mechanical allodynia and thermal hyperalgesia induced by OXL-induced sensory neuropathy. MSC increased the gene expression of antioxidant factors SOD and Nrf-2, elevated the levels of anti-inflammatory cytokines IL-10 and TGF-beta in the spinal cord of neuropathic mice, and decreased nitrite and MDA levels, possibly inducing the reversal of OXL-induced sensory neuropathy by activating anti-inflammatory and antioxidant pathways.
Article
Infectious Diseases
Kanae Yamashita, Yoshimitsu Shimomura, Hiroaki Ikesue, Nobuyuki Muroi, Akihiro Yoshimoto, Tohru Hashida
Summary: The study found that low-dose TMP-SMX is effective and safe for PCP prophylaxis in patients undergoing hemodialysis, with a significantly lower cumulative discontinuation rate due to adverse events compared to the standard-dose group.
BMC INFECTIOUS DISEASES
(2021)
Article
Multidisciplinary Sciences
Misaki Inoue, Kiyoka Matsumoto, Mizuki Tanaka, Yu Yoshida, Riko Satake, Fumiya Goto, Kazuyo Shimada, Ririka Mukai, Shiori Hasegawa, Takaaki Suzuki, Hiroaki Ikesue, Jun Liao, Tohru Hashida, Mitsuhiro Nakamura
Summary: Chemotherapy-induced peripheral neuropathy (CIPN) is a common adverse event associated with several anticancer drugs. Analysis of the Japanese Adverse Drug Event Report (JADER) database revealed that certain drugs, such as vinca alkaloids, taxanes, platinum compounds, and monoclonal antibodies, have a high risk for CIPN development, with varying time-to-onset and outcomes. CIPN caused by nab-paclitaxel shows a faster onset compared to sb-paclitaxel, and early treatment may be necessary for patients who receive taxanes or monoclonal antibodies and do not show improvement.
SCIENTIFIC REPORTS
(2021)
Article
Pharmacology & Pharmacy
Riko Satake, Kiyoka Matsumoto, Mizuki Tanaka, Ririka Mukai, Kazuyo Shimada, Yu Yoshida, Misaki Inoue, Shiori Hasegawa, Kazuhiro Iguchi, Hiroaki Ikesue, Shinya Shimizu, Shohei Nishida, Akio Suzuki, Tohru Hashida, Mitsuhiro Nakamura
Summary: Drug-induced gastrointestinal obstruction and perforation can result in life-threatening complications. Different drug categories have varying onset times for adverse events, highlighting the importance of detailed monitoring to prevent fatal consequences.
FRONTIERS IN PHARMACOLOGY
(2021)
Article
Immunology
Tetsushu Onita, Kazuro Ikawa, Noriyuki Ishihara, Hiroki Tamaki, Takahisa Yano, Kohji Naora, Norifumi Morikawa
Summary: PK models of ampicillin and sulbactam were developed, and the recommended dosage for empirical therapy of community-acquired pneumonia is 75mg/kg q.i.d.
PEDIATRIC INFECTIOUS DISEASE JOURNAL
(2022)
Article
Oncology
Hiroaki Ikesue, Kohei Doi, Mayu Morimoto, Masaki Hirabatake, Nobuyuki Muroi, Shinsuke Yamamoto, Toshihiko Takenobu, Tohru Hashida
Summary: This study found that patients treated with denosumab for bone metastasis have a higher risk of developing medication-related osteonecrosis of the jaw (MRONJ) compared to those treated with zoledronic acid, highlighting the need for close monitoring for patients on denosumab.
SUPPORTIVE CARE IN CANCER
(2022)
Article
Oncology
Hiroaki Ikesue, Kenta Yamaoka, Ayako Matsumoto, Masaki Hirabatake, Nobuyuki Muroi, Toshinari Yamasaki, Mutsushi Kawakita, Tohru Hashida
Summary: This study investigated the risk factors for proteinuria and the protective effect of renin-angiotensin system (RAS) inhibitors in patients with renal cell carcinoma (RCC) receiving axitinib. The results showed that pre-existing proteinuria and non-RAS inhibitor use were significantly associated with the development of higher-grade proteinuria.
CANCER CHEMOTHERAPY AND PHARMACOLOGY
(2022)
Article
Pharmacology & Pharmacy
Masaki Hirabatake, Hiroaki Ikesue, Yuna Iwama, Kei Irie, Shintaro Yoshino, Toshinari Yamasaki, Tohru Hashida, Mutsushi Kawakita, Nobuyuki Muroi
Summary: The study investigated the efficacy of a collaborative management program between pharmacists and urologists for CRPC patients receiving enzalutamide, and found that collaborative management was useful for prolonging the time to enzalutamide discontinuation.
FRONTIERS IN PHARMACOLOGY
(2022)
Article
Nutrition & Dietetics
Tomoki Takase, Naoko Tsugawa, Takayuki Sugiyama, Hiroaki Ikesue, Masaaki Eto, Tohru Hashida, Keisuke Tomii, Nobuyuki Muroi
Summary: This study demonstrated a significant association between low serum 25(OH)D levels and severe COVID-19 among Japanese patients, suggesting that vitamin D status may be an independent risk factor for severe illness.
CLINICAL NUTRITION ESPEN
(2022)
Article
Biochemistry & Molecular Biology
Keisuke Mine, Takehiro Kawashiri, Mizuki Inoue, Daisuke Kobayashi, Kohei Mori, Shiori Hiromoto, Hibiki Kudamatsu, Mayako Uchida, Nobuaki Egashira, Satoru Koyanagi, Shigehiro Ohdo, Takao Shimazoe
Summary: This study investigates the preventive effect of omeprazole on oxaliplatin-induced peripheral neuropathy.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2022)
Article
Pharmacology & Pharmacy
Tetsushu Onita, Noriyuki Ishihara, Amika Ikebuchi, Takahisa Yano, Nobuhiro Nishimura, Hiroki Tamaki, Kazuro Ikawa, Norifumi Morikawa, Kohji Naora
Summary: The safety target achievement rate estimated by the PK/PD simulation may represent an important index for risk assessment of LZD-induced thrombocytopenia, and this risk increases with the duration of LZD therapy.
JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS
(2022)
Article
Pharmacology & Pharmacy
Shiori Hasegawa, Hiroaki Ikesue, Riko Satake, Misaki Inoue, Yu Yoshida, Mizuki Tanaka, Kiyoka Matsumoto, Wataru Wakabayashi, Keita Oura, Nobuyuki Muroi, Tohru Hashida, Kazuhiro Iguchi, Mitsuhiro Nakamura
Summary: This study evaluated and compared the time-to-onset profile for medication-related osteonecrosis of the jaw associated with denosumab in treatment-naive and pre-treated patients with zoledronic acid. The results showed a shorter onset time in the post-zoledronic acid group and highlighted the importance of considering the early risk of medication-related osteonecrosis of the jaw when switching patients from zoledronic acid to denosumab treatment.
DRUGS-REAL WORLD OUTCOMES
(2022)
Article
Pharmacology & Pharmacy
Tomoki Takase, Norio Masumoto, Naoki Shibatani, Yusaku Matsuoka, Fumiaki Tanaka, Masaki Hirabatake, Hiroko Kashiwagi, Itaru Nishioka, Hiroaki Ikesue, Tohru Hashida, Naoshi Koide, Nobuyuki Muroi
Summary: This study evaluated the effect of automated dispensing robots and collaborative work with pharmacy support staff on medication dispensing. The results showed that the introduction of robotic dispensing system significantly reduced the incidence of dispensing errors and the dispensing time of pharmacists. The robotic dispensing system could partially replace the work of pharmacists and enhance the clinical care for patients.
JOURNAL OF PHARMACEUTICAL HEALTH CARE AND SCIENCES
(2022)
Article
Medical Laboratory Technology
Makiko Tohi, Kei Irie, Tomoyuki Mizuno, Hiroyuki Okuyoshi, Masaki Hirabatake, Hiroaki Ikesue, Nobuyuki Muroi, Masaaki Eto, Shoji Fukushima, Keisuke Tomii, Tohru Hashida
Summary: This study aimed to characterize the real-world population pharmacokinetics (PK) of nivolumab in Japanese patients with non-small cell lung cancer (NSCLC). Population PK analysis revealed that clearance of nivolumab was influenced by factors such as serum albumin level, estimated glomerular filtration rate, and treatment period. Further studies are needed to determine optimal dosing regimens for these patients.
THERAPEUTIC DRUG MONITORING
(2023)
Article
Pharmacology & Pharmacy
Hiroaki Ikesue, Haruna Yamamoto, Masaki Hirabatake, Tohru Hashida, Hobyung Chung, Tetsuro Inokuma, Nobuyuki Muroi
Summary: Proteinuria is a common adverse event in patients with hepatocellular carcinoma (HCC) receiving lenvatinib treatment. This study retrospectively reviewed the medical records of HCC patients receiving lenvatinib and identified lower baseline estimated glomerular filtration rate (eGFR) as a risk factor for developing proteinuria.
BIOLOGICAL & PHARMACEUTICAL BULLETIN
(2022)
Article
Pharmacology & Pharmacy
Fumiaki Tanaka, Naoki Shibatani, Kazumi Fujita, Hiroaki Ikesue, Satoru Yoshimizu, Nobuyuki Muroi, Yasuo Kurimoto, Tohru Hashida
Summary: In this study, it was found that about 20% of patients with PACD received medications potentially contraindicated for PACD, such as anticholinergics. Attention should be paid to patients prescribed multiple drugs for adverse events, such as increase in intraocular pressure.
JOURNAL OF PHARMACEUTICAL HEALTH CARE AND SCIENCES
(2021)